|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BACKGROUND In the present study, we aimed to retrospectively analyze the correlation between toxicity of pemetrexed (PEM) chemotherapy and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in patients with advanced non-squamous non-small cell lung cancer (non-sq NSCLC).
|
29186089 |
2017 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.
|
23463763 |
2013 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The MTHFR C677T polymorphism might be a genetic marker for lung cancer risk or response to platinum- based chemotherapy in advanced NSCLC.
|
24142642 |
2013 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Cancer-testis gene expression is associated with the methylenetetrahydrofolate reductase 677 C>T polymorphism in non-small cell lung carcinoma.
|
24063603 |
2013 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Using a genetic model analysis, the polymorphism MTHFR 677 C→T</span> showed a significantly increased risk for NSCLC in women but not in men, which was observed in the codominant model (CT vs CC adjusted odds ratio [OR] = 2.46; 95% confidence interval [CI]: 1.37-4.42; p = 0.003; TT vs CC adjusted OR: 2.04; 95% CI: 1.09-3.81; p = 0.03) and the dominant model (CT + TT vs CC adjusted OR: 2.30; 95% CI: 1.31-4.05; p = 0.004).
|
21605004 |
2011 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In the present study, multiple genetic polymorphisms, TS VNTR, TS SNP and MTHFR C677T, were analyzed in NSCLC and compared with clinicopathological features and patients' prognoses.
|
16334126 |
2006 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In the present study, we have examined the SNP of methylenetetrahydrofolate reductase (MTHFR) C677T, which affects DNA methylation patterns and is linked to elevated plasma homocysteine levels in 208 patients with gemcitabine/cisplatin-treated stage IV non-small-cell lung cancer (NSCLC).
|
15217535 |
2004 |
|
rs1217691063
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer.
|
12883704 |
2004 |
|
rs397507444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In the stratified analyses, we observed only the A1298C polymorphism in the CC genotype carriers with a statistically significant reduction in the risk of non-small-cell lung cancer, compared to the AA genotype carriers.
|
30323671 |
2018 |
|
rs397507444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer.
|
12883704 |
2004 |
|
rs1801133
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, the current study highlights <i>MTHFR</i> rs1801133 G>A variants decreases the risk of NSCLC.
|
29299150 |
2017 |
|
rs9651118
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, <i>MTHFR</i> rs9651118 T>C polymorphism increased the risk of NSCLC in < 60 years, never smoking and BMI < 24 kg/m<sup>2</sup> subgroups.
|
29299150 |
2017 |
|
rs1537514
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy.
|
25104092 |
2014 |